Mekhail Extension of the Motzer Score

ورودی‌های بالینی بیمار

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
mekhail score
—points
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • Favorable Risk0–1
  • Intermediate Risk2–2
  • Poor Risk3–6
Direct Clinical Answer

The Mekhail Extension of the Motzer Score calculator is designed for bedside predicting survival of metastatic renal cell carcinoma, more accurately than the original Motzer Score by incorporating additional prognostic factors in clinical practice. The resulting score directly guides clinician decision-making regarding adjusting systemic antineoplastic.

Clinical Guidelines & Evidence

Predicts survival of metastatic renal cell carcinoma, more accurately than the original Motzer Score by incorporating additional prognostic factors

Clinical Indication

The Mekhail Extension of the Motzer Score is indicated for bedside clinical practice to support Predicts survival of metastatic renal cell carcinoma, more accurately than the original Motzer Score by incorporating additional prognostic factors. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients with solid tumors or hematologic malignancies undergoing staging, systemic therapy tolerability assessment, or prognostic stratification. Clinical application is indicated across Medical oncology clinics, chemotherapy infusion suites, inpatient oncology services, and palliative care.

Limitations & Contraindications

Prognostic indices provide statistical cohort survival estimates and must not replace individualized patient goals of care.

Clinical Pearls & Action Plan

Standardized functional performance status (ECOG or Karnofsky) is an independent determinant of chemotherapy tolerance and survival.

Formula & Variables:

Score = Sum of present risk factors (each factor = 1 point if present)

Input Parameters

NameTypeRequiredDescription
ldh_elevatedstringYesLDH > 1.5x upper limit of normal (ULN). Normal ULN is typically 140 U/L
hemoglobin_lowstringYesHemoglobin < lower limit of normal (typically <12 g/dL)
corrected_calcium_highstringYesCorrected serum calcium > 10 mg/dL (2.5 mmol/L)
time_to_treatment_less_than_1_yearstringYesTime from initial diagnosis to systemic treatment < 1 year
prior_radiotherapystringYesPrior treatment with radiation therapy
metastatic_sites_2_or_morestringYes≥2 sites of metastasis

Score Interpretation & Guidance

RangeStageDescription
0–1Favorable Risk0-1 risk factors
2–2Intermediate Risk2 risk factors
3–6Poor Risk≥3 risk factors

Evidence-Based References (EBM)

  • Mekhail TM, Abou-Jawde RM, Boumerhi G, Malhi S, Wood L, Elson P, et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol. 2005 Feb 1;23(4):832-41. doi: 10.1200/JCO.2005.05.179.DOI: 10.1200/JCO.2005.05.179
  • Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999 Aug;17(8):2530-40. doi: 10.1200/JCO.1999.17.8.2530.DOI: 10.1200/JCO.1999.17.8.2530

Related calculators